Holen Sie sich die Stockscreener-App
3.68
7.07%
-0.28
Handel nachbörslich:
3.67
-0.01
-0.27%
Schlusskurs vom Vortag:
$3.96
Offen:
$3.85
24-Stunden-Volumen:
85,699
Relative Volume:
0.98
Marktkapitalisierung:
$157.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-6.9434
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
-11.11%
1M Leistung:
-40.74%
6M Leistung:
-16.17%
1J Leistung:
+31.43%
1-Tages-Spanne:
$3.5052
$3.86
1-Wochen-Bereich:
$3.47
$4.24
52-Wochen-Spanne:
$2.14
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
3.68 | 157.71M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 - Defense World
Equities Analysts Offer Predictions for DMAC Q1 Earnings - Defense World
DiaMedica Therapeutics Reports 2024 Financial Results - TipRanks
DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares - Business Wire
H.C. Wainwright lifts DiaMedica stock target to $10 on trial hopes - Investing.com Canada
H.C. Wainwright lifts DiaMedica stock target to $10 on trial hopes By Investing.com - Investing.com South Africa
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ... - Yahoo
DiaMedica Therapeutics’ Optimistic Earnings Call Highlights - TipRanks
Earnings call transcript: DiaMedica Q4 2024 results and stock surge By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Q4 2024 results and stock surge - Investing.com India
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results - BioSpace
DiaMedica Therapeutics Reports 2024 Financial Results and Strategic Advancements - TipRanks
DiaMedica Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DIAMEDICA THERAPEUTICS Earnings Results: $DMAC Reports Quarterly Earnings - Nasdaq
Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics - Yahoo Finance
Where are the Opportunities in (DMAC) - Stock Traders Daily
DIAMEDICA THERAPEUTICS Earnings Preview: Recent $DMAC Insider Trading, Hedge Fund Activity, and More - Nasdaq
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 - Business Wire
DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Tuesday - Defense World
Insiders At DiaMedica Therapeutics See Good Returns After Buying Stock Worth US$9.00m - Simply Wall St
DiaMedica Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
DiaMedica announces board member Richard Pilnik’s retirement - Investing.com
DiaMedica announces board member Richard Pilnik’s retirement By Investing.com - Investing.com South Africa
Trading (DMAC) With Integrated Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Takes $81,000 Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Appoints Daniel J. O’Connor to Board - MSN
DiaMedica welcomes new board member with biopharma leadershi By Investing.com - Investing.com Nigeria
DiaMedica welcomes new board member with biopharma leadershi - Investing.com
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors - Business Wire
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 8.4% in January - MarketBeat
DiaMedica reports on DM199 stroke treatment mechanism By Investing.com - Investing.com Nigeria
DiaMedica reports on DM199 stroke treatment mechanism - Investing.com
DiaMedica Therapeutics Announces Publication Of Dm199'S Mechanism Of Action For The Treatment Of Acute Ischemic Stroke In The Journal Stroke - Marketscreener.com
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke - Business Wire
Learn to Evaluate (DMAC) using the Charts - Stock Traders Daily
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
DiaMedica's Game-Changing Stroke Treatment Takes Center Stage at Major Healthcare Conference (DMAC) - Stock Titan
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 14.5% - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Here's Why - MarketBeat
DiaMedica Therapeutics: Interesting Work In Treating Ischemic Stroke - Seeking Alpha
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):